A 51-Year-Old Woman with Advanced Peritoneal Mesothelioma and Stage 3b Chronic Kidney Disease Treated with Cytoreductive Surgery and Bidirectional Intraperitoneal Cisplatin and Ifosfamide Chemotherapy: A Case Report

Overview

Journal Am J Case Rep

Specialty General Medicine

Date 2023 Dec 14

PMID 38093612

Authors

Marwan Alaswad

Fadwa Elkordy

Heba Jaamour

Abdullah Al Otry

Ayman Z Azzam

Tarek M Amin

Hatim A Khoja

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Malignant mesotheliomas are rare, yet highly malignant tumors. Mesotheliomas are tumors that develop from mesothelial surfaces, with the pleura being the most common, followed by the peritoneum. The diagnosis of malignant peritoneal mesothelioma (MPM) is usually established when the disease is advanced, owing to the nonspecific clinical appearance and abdominal symptoms. Initially, MPM was treated with palliative systemic chemotherapy, with or without palliative surgery. However, cytoreductive surgery (CRS) combined with bidirectional intraoperative chemotherapy (BDIC) has recently emerged as a treatment option for MPM. BDIC creates a bidirectional chemotherapy gradient in the peritoneal tumor cells through the simultaneous use of intraperitoneal and intravenous chemotherapy. CRS, combined with BDIC (CRS-BDIC), allows the complete elimination of residual tiny tumor cells after complete removal of the visible tumor nodules. CASE REPORT Herein, we present a case of a 51-year-old woman with MPM and chronic kidney disease (CKD) stage 3b. Her treatment consisted of neoadjuvant chemotherapy and immunotherapy, followed by CRS-BDIC using intraperitoneal cisplatin and doxorubicin, and intravenous ifosfamide. The surgery was successful, with no immediate complications or decline in the patient's kidney function. On follow up 2 months later, the patient denies suffering any chemotherapy-related adverse effects, and her kidney profile remains stable. CONCLUSIONS In conclusion, nephrotoxicity, a known adverse effect of cisplatin and ifosfamide, might not be a contraindication for the use of these potentially nephrotoxic drugs in CRS-BDIC in patients with renal impairment.

References

de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O . Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2019; 2(2):47-62. PMC: 6405033. DOI: 10.1515/pp-2017-0010. View

Sutton R, Walker V, Halabe A, Swenerton K, Coppin C . Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med. 1991; 117(1):40-3. View

van Der Speeten K, Stuart O, Mahteme H, Sugarbaker P . Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2012; 2011:185092. PMC: 3263669. DOI: 10.1155/2011/185092. View

Suer E, Mermerkaya M, Gulpinar O, Afandiyev F, Baltaci S, Turkolmez K . Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?. J Urol. 2013; 190(6):2081-5. DOI: 10.1016/j.juro.2013.06.009. View

Arany I, Safirstein R . Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23(5):460-4. DOI: 10.1016/s0270-9295(03)00089-5. View

Launay-Vacher V, Rey J, Isnard-Bagnis C, Deray G, Daouphars M . Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008; 61(6):903-9. DOI: 10.1007/s00280-008-0711-0. View

Miller R, Tadagavadi R, Ramesh G, Reeves W . Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2011; 2(11):2490-518. PMC: 3153174. DOI: 10.3390/toxins2112490. View

Morgan K, Snavely A, Wind L, Buie L, Grilley-Olson J, Walko C . Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol. Ann Pharmacother. 2014; 48(7):863-869. DOI: 10.1177/1060028014533303. View

Sastry J, Kellie S . Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005; 22(5):441-5. DOI: 10.1080/08880010590964381. View

10.

Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard A, Bakrin N . What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. J Surg Oncol. 2016; 113(7):796-803. DOI: 10.1002/jso.24248. View

11.

Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G . Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010; 2(2):68-75. PMC: 2999165. DOI: 10.4251/wjgo.v2.i2.68. View

12.

Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D . Long-term renal effect of cisplatin in man. Am J Nephrol. 1994; 14(2):81-4. DOI: 10.1159/000168693. View

13.

Antman K, Hassan R, Eisner M, Ries L, Edwards B . Update on malignant mesothelioma. Oncology (Williston Park). 2005; 19(10):1301-9. View

14.

Almesned R, Azzam A, Aldeheshi A, Amin T . Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report. Am J Case Rep. 2023; 24:e938192. PMC: 10052470. DOI: 10.12659/AJCR.938192. View

15.

Acherman Y, Welch L, Bromley C, Sugarbaker P . Clinical presentation of peritoneal mesothelioma. Tumori. 2003; 89(3):269-73. DOI: 10.1177/030089160308900307. View

16.

Helm J, Miura J, Glenn J, Marcus R, Larrieux G, Jayakrishnan T . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2014; 22(5):1686-93. DOI: 10.1245/s10434-014-3978-x. View

17.

Hakeam H, Breakiet M, Azzam A, Nadeem A, Amin T . The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014; 36(10):1486-91. DOI: 10.3109/0886022X.2014.949758. View

18.

Hakeam H, Ayman A, Waleed A, Amen T . Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin. Pleura Peritoneum. 2019; 4(4):20190025. PMC: 6881663. DOI: 10.1515/pp-2019-0025. View

19.

Li C, Alexander Jr H . Peritoneal Metastases from Malignant Mesothelioma. Surg Oncol Clin N Am. 2018; 27(3):539-549. DOI: 10.1016/j.soc.2018.02.010. View

20.

Kintzel P, Dorr R . Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21(1):33-64. DOI: 10.1016/0305-7372(95)90010-1. View